Guardant Health announces Palmetto GBA LCD expanding Guardant360 assay coverage Health announced that Palmetto GBA, a Medicare administrative contractor, has posted a draft local coverage determination, or LCD, expanding Medicare coverage of the Guardant360 assay from advanced non-small cell lung cancer, or NSCLC, to over a dozen advanced solid tumor cancer types with guideline-recommended genomic targets. The draft LCD would apply to advanced cancer patients who are covered by Medicare for next-generation sequencing of tumor tissue, but have insufficient or unavailable tissue samples. These cases may comprise a significant percentage of advanced cancers, especially those that have spread to the deep viscera, bone or brain.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.